Paula Tabares, PhD

Paula Tabares, Immunomonitoring, MRD diagnostics, multiple myeloma, cancer, Würzburg University Hospital, TGN1412, TAB08, Thomas Hünig, Andreas Beilhackjoined the Experimental Stem Cell Transplantation Laboratory as postdoctoral fellow in May 2018. After finishing her studies in Chemistry in Colombia, she moved to Germany in autumn 2007 for her PhD studies under the supervision of Prof. Ute Hentschel and Prof. Thomas Hünig. Her doctoral thesis involved the identification of marine sponge derived secondary metabolites with immunological activity. In January 2012, she joined the group of Prof. Hünig as a postodoctoral fellow, where she employed a novel in vitro system to study the effects of the CD28 superagonist TGN1412 (now TAB08) on the induction of cytotoxic effecor cells and cytokines versus regulatory T-cells. Using healthy volunteers as well as RA patients, she made the observation that the detrimental side effects can be separated from the intended benficial effect (induction of regulatory T-cells) in a dose depependent manner. In her current research, she evaluates the phenotypic profile of cancer cells and tumor microenvironment throughout the course of the disease in patients with multiple myeloma (MM) utilizing multiparameter flow cytometry. Furthermore, she established two nine-color flow cytometry panels to evaluate minimal residual disease (MRD) in MM patients, which is an essential tool to assess treatment effectiveness and has been correlated with patient overall survival. Lately, she established and pursues the routine measurement of circulating tumor cells (liquid biopsy) that provides real-time insights in disease-state and response to therapy in cancer patients.


Dr. Paula Tabares, PhD

Tel: +49-931-201 44055 (office)

Tel: +49-931-201 27637 (lab)


Solimando AG, Desantis V, Palumbo C, Marasco C, Pappagallo F, Montagnani M, Ingravallo G, Cicco S, Di Paola R, Tabares P, Beilhack A, Dammacco F, Ria R, Vacca A. (2023). STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure. Clin Exp Med, in press

Böckle D, Tabares P, Zhou X, Schimanski S, Steinhardt MJ, Bittrich M, Seebacher E, Ulbrich M, Wilnit A, Metz C, Heidemeier A, Bley T, Werner R, Buck A, Einsele H, Kortüm KM, Beilhack A*, Rasche L*. (2022). MRD and imaging guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. British Journal of Haematology 198(3):515-522.

Brandl A, Solimando AG, Mokhtari Z, Tabares P, Medler P, Manz H, Da Via M, Croci GA, Kurzwart M, Thusek S, Schneider T, Ebert R, Jakob F, Einsele H, Beilhack A. (2022). Junctional Adhesion Molecule-C expression specifies a CD138low/neg multiple myeloma cell population in mice and men. Blood Advances 6(7):2195-2206.

Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T, Wilnit A, Mokhtari Z, Tabares P, Böckle D, Rasche L, Martin Kortüm K, Lutz MB, Einsele H, Brandl A, Beilhack A. (2022). Transient regulatory T cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia 36(3):790-800.

Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm KM, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A. (2021). Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica 106(7):1943-1956.

Tabares P, Berr S, Langenhorst D, Sawitzki B, Ten Berge I, Tony HP, Hünig T. (2018). Short -term cytokine stimulation reveals regulatory T -cells with down-regulated Foxp3 expression in human peripheral blood. Eur J Immunol. 48(2):366-379.

Langenhorst D, Tabares P, Gulde T, Becklund BR, Berr S, Surh CD, Hünig T. (2018). Self-Recognition Sensitizes Mouse and Human Regulatory T-cells to Low-Dose CD28 Superagonist Stimulation. Front Immunol. 8:1985.

Tyrsin D, Chuvpilo S, Matskevich1 A, Nemenov D, Römer PS, Tabares P and Hünig, T. (2016). From TGN1412 to TAB08: The return of CD28 superagonist therapy to clinical development for the treatment of Rheumatoid Arthritis. Clin Exp Rheumatol. 34(4,S98):45-8.

Tabares P, Berr S, Römer PS, Chuvpilo S, Matskevich AA, Tyrsin D, Fedotov Y, Einsele H, Tony HPand Hünig T. (2014). Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol. 44(4):1225-36.

Bartholomaeus P, Semmler LY, Bukur T, Boisguerin V, Römer PS, Tabares P, Chuvpilo S, Tyrsin DY, Matskevich A, Hengel H, Castle J, Hünig T and Kalinke U. (2014). Cell Contact-Dependent Priming and Fc Interaction with CD32+ Immune Cells Contribute to the TGN1412-Triggered Cytokine Response. J Immunol. 192(5):2091-8.

Tabares P, Degel J, Schaschke N, Hentschel U and Schirmeister T. (2012). Identification of the protease inhibitor miraziridine A in the Red Sea sponge Theonella swinhoei. Pharmacognosy Res. 4(1):63-6.

Tabares P, Pimentel-Elardo S, Hünig T, Schirmeister T and Hentschel U. (2011). Anti-protease and immunomodulatory activities of bacteria associated with Caribbean sponges. Mar Biotechnol (NY) 13(5):883-92.

Forero JE, Avila L, Taborda N, Tabares P, López A, Torres F, Quiñones W, Bucio MA, Mora-Pérez Y, Rugeles MT, Joseph-Nathan P and Echeverri F. (2008). In vitro anti-influenza screening of several Euphorbiaceae species: Structure of a bioactive Cyanoglucoside from Codiaeum variegatum. Phytochemistry 69(16):2815-9.